Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437753 | 0.90 | UTS2R (0.58) | UTS2RMEN1KMT2AEPHX2 | |
| SCHEMBL14435679 | 0.89 | UTS2R (0.47) | UTS2RMEN1KMT2A | |
| SCHEMBL2214246 | 0.86 | EPHX2 (0.55) | UTS2REPHX2 | |
| SCHEMBL12437763 | 0.85 | UTS2R (0.51) | UTS2RSLC2A1MEN1KMT2A | |
| SCHEMBL12437766 | 0.85 | HRH3 (0.59) | UTS2RMEN1KMT2A | |
| SCHEMBL12437948 | 0.84 | SLC5A7 (0.56) | UTS2RMEN1KMT2A | |
| SCHEMBL12437764 | 0.84 | UTS2R (0.64) | UTS2R | |
| SCHEMBL12437947 | 0.83 | SLC5A7 (0.56) | MEN1KMT2A | |
| SCHEMBL12437944 | 0.83 | KMT2A (0.47) | UTS2RMEN1KMT2AEPHX2 | |
| SCHEMBL12437853 | 0.83 | SLC2A1 (0.44) | UTS2RSLC2A1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885SLC2A1 3508/4885MEN1 3974/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885SLC2A1 3508/4885MEN1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.